|
|
Volumn 22, Issue 2, 2004, Pages 137-138
|
|
Genomics companies shop around for chemical expertise
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CG 53135;
CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE;
DG 031;
DRUG;
ELVUCITABINE;
LG 617;
LG 653;
UNCLASSIFIED DRUG;
XL 784;
CARDIOVASCULAR RISK;
CHEMISTRY;
CLINICAL RESEARCH;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG TARGETING;
EXPERT SYSTEM;
GENETIC CODE;
GENOMICS;
HEART INFARCTION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
ICELAND;
INVESTMENT;
LICENSING;
MOUSE;
NONHUMAN;
NOTE;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
CHEMICAL INDUSTRY;
COOPERATIVE BEHAVIOR;
DRUG DESIGN;
DRUG INDUSTRY;
GENOMICS;
INTERINSTITUTIONAL RELATIONS;
LICENSURE;
PROFESSIONAL COMPETENCE;
UNITED STATES;
HUMAN IMMUNODEFICIENCY VIRUS;
|
|
EID: 0742270992
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt0204-137 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|